Resources

Press Release

July 17th, 2024

CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts

Blog
May 21st, 2024

Revolutionizing IBD Treatment: The CytoReason and CCF Partnership

Press Release

May 15th, 2024

CytoReason and the Crohn’s & Colitis Foundation Forge Groundbreaking Data Collaboration to Advance IBD Research

Scientific Publications
October 27th, 2023

Reconstructing disease dynamics for mechanistic insights and clinical benefit

Blog
August 22nd, 2023

Navigating Drug Development: CytoReason’s Disease Model Platform

Find out more about the Disease Model Platform by watching our new video
Scientific Publications
June 21st, 2023

Peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs

Media Coverage
February 1st, 2023

Making Clinical Trials Better for Everyone in 2023

Media Coverage
January 31st, 2023

Roundtable: What do you view as the most disruptive or transformational technology or development on the horizon?

Media Coverage
January 27th, 2023

Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances

resoucres filter

Bring your data to life

Skip to content